A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
Latest Information Update: 28 Jan 2024
At a glance
- Drugs NP 751 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors NanoPharmaceuticals
- 15 Sep 2023 Planned number of patients changed from 28 to 34.
- 15 Sep 2023 Planned End Date changed from 1 Aug 2024 to 1 Oct 2025.
- 15 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Oct 2024.